LLY PE Ratio & Valuation, Is LLY Overvalued

Historical Valuation

Eli Lilly and Co (LLY) is now in the Fair zone, suggesting that its current forward PE ratio of 34.51 is considered Fairly compared with the five-year average of 40.93. The fair price of Eli Lilly and Co (LLY) is between 875.05 to 1400.87 according to relative valuation method.

Relative Value

Fair Zone

875.05-1400.87

Current Price：995.41

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Eli Lilly and Co (LLY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Eli Lilly and Co (LLY) has a current Price-to-Book (P/B) ratio of 40.68. Compared to its 3-year average P/B ratio of 47.14, the current P/B ratio is approximately -13.72% higher. Relative to its 5-year average P/B ratio of 39.96, the current P/B ratio is about 1.80% higher. Eli Lilly and Co (LLY) has a Forward Free Cash Flow (FCF) yield of approximately 0.96%. Compared to its 3-year average FCF yield of 0.53%, the current FCF yield is approximately 79.56% lower. Relative to its 5-year average FCF yield of 1.34%, the current FCF yield is about -28.27% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LLY competitors is 7.02, providing a benchmark for relative valuation. Eli Lilly and Co Corp (LLY.N) exhibits a P/S ratio of 13.21, which is 88.17% above the industry average. Given its robust revenue growth of 42.56%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LLY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LLY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LLY currently overvalued or undervalued?

What is Eli Lilly and Co (LLY) fair value?

LLY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Eli Lilly and Co (LLY) is between 875.05 to 1400.87 according to relative valuation method.

How does LLY's valuation metrics compare to the industry average?

The average P/S ratio for LLY's competitors is 7.02, providing a benchmark for relative valuation. Eli Lilly and Co Corp (LLY) exhibits a P/S ratio of 13.21, which is 88.17% above the industry average. Given its robust revenue growth of 42.56%, this premium appears sustainable.

What is the current P/B ratio for Eli Lilly and Co (LLY) as of Mar 09 2026?

As of Mar 09 2026, Eli Lilly and Co (LLY) has a P/B ratio of 40.68. This indicates that the market values LLY at 40.68 times its book value.

What is the current FCF Yield for Eli Lilly and Co (LLY) as of Mar 09 2026?

As of Mar 09 2026, Eli Lilly and Co (LLY) has a FCF Yield of 0.96%. This means that for every dollar of Eli Lilly and Co's market capitalization, the company generates 0.96 cents in free cash flow.

What is the current Forward P/E ratio for Eli Lilly and Co (LLY) as of Mar 09 2026?

As of Mar 09 2026, Eli Lilly and Co (LLY) has a Forward P/E ratio of 34.51. This means the market is willing to pay $34.51 for every dollar of Eli Lilly and Co's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Eli Lilly and Co (LLY) as of Mar 09 2026?

As of Mar 09 2026, Eli Lilly and Co (LLY) has a Forward P/S ratio of 13.21. This means the market is valuing LLY at $13.21 for every dollar of expected revenue over the next 12 months.

LLY Valuation